ViGenCell Company Description

ViGenCell Inc. specializes in immune cell therapy.

It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use.

The company was founded in 1995 and is based in Seoul, South Korea.

ViGenCell Inc.

Country	South Korea
Founded	1995
Industry	Biological Products, Except Diagnostic Substances
CEO	Kim Tai Gyu

Contact Details

Address: Omnibus Park Building B(B-dong) Seoul, 06591 South Korea
Phone	82 2 2127 7590
Website	vigencell.com

Stock Details

Ticker Symbol	308080
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Kim Tai Gyu	Chief Executive Officer